NUVB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Nuvation Bio Inc (NUVB) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has promising developments with its drug IBTROZI and a significant revenue increase in Q4 2025, the stock faces negative sentiment from insider selling, ongoing securities fraud investigations, and a recent sharp price drop. Additionally, technical indicators and options data do not suggest strong bullish momentum. A hold is recommended until clearer positive catalysts emerge.
The MACD histogram is negative and contracting, RSI is neutral at 26.52, and moving averages are converging, indicating no strong trend. The stock is trading near its support level of 4.211, with resistance at 4.742. Overall, the technical indicators do not suggest a strong buy signal.
IBTROZI has shown strong efficacy with a median Duration of Response of 50 months in TKI-naïve patients with ROS1+ non-small cell lung cancer.
Upcoming presentations at the AACR Annual Meeting may provide further positive data on IBTROZI.
FDA approval for IBTROZI in June 2025 marks a significant milestone.
Insider selling has increased by 287.18% over the last month.
Securities fraud investigation by Pomerantz LLP may impact investor confidence.
Revenue growth concerns due to treatment discontinuations among later-line patient populations.
Recent stock price drop of 25.3% following revenue-related news.
In Q4 2025, revenue increased significantly by 633.06% YoY to $41.87M, but net income dropped by 25.99% YoY to -$36.59M, and EPS declined by 26.67% to -$0.11. Gross margin improved to 96.94%, up 270.28% YoY, indicating strong operational efficiency despite profitability challenges.
Analysts have mixed views. UBS lowered its price target to $7 with a Neutral rating, while RBC Capital and Truist raised their price targets to $13, maintaining Outperform and Buy ratings, respectively. Analysts see potential in IBTROZI but acknowledge near-term revenue challenges.
